JP2006508109A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508109A5 JP2006508109A5 JP2004550659A JP2004550659A JP2006508109A5 JP 2006508109 A5 JP2006508109 A5 JP 2006508109A5 JP 2004550659 A JP2004550659 A JP 2004550659A JP 2004550659 A JP2004550659 A JP 2004550659A JP 2006508109 A5 JP2006508109 A5 JP 2006508109A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridazin
- nonane
- diazabicyclo
- disease
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 3
- 230000016160 smooth muscle contraction Effects 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- -1 indol-2-yl- Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- SPENYPHOPYNNMM-UHFFFAOYSA-N 2-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyridazin-3-yl]-1,3,4-oxadiazole Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=NN=CO1 SPENYPHOPYNNMM-UHFFFAOYSA-N 0.000 claims 1
- NWBQHUOIZCLTEN-UHFFFAOYSA-N 2-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyridazin-3-yl]-1,3,4-thiadiazole Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=NN=CS1 NWBQHUOIZCLTEN-UHFFFAOYSA-N 0.000 claims 1
- GQDZMLYERQCVCI-UHFFFAOYSA-N 2-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyridazin-3-yl]-1,3-oxazole Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=NC=CO1 GQDZMLYERQCVCI-UHFFFAOYSA-N 0.000 claims 1
- LWDIJZHGOFRRBY-UHFFFAOYSA-N 2-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyridazin-3-yl]-1,3-thiazole Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=NC=CS1 LWDIJZHGOFRRBY-UHFFFAOYSA-N 0.000 claims 1
- XGQNMFLIMAXOIY-UHFFFAOYSA-N 4-(6-pyridin-3-ylpyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=CC=CN=C1 XGQNMFLIMAXOIY-UHFFFAOYSA-N 0.000 claims 1
- DKHBMBRMHHQCDB-UHFFFAOYSA-N 4-(6-selenophen-2-ylpyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=CC=C[se]1 DKHBMBRMHHQCDB-UHFFFAOYSA-N 0.000 claims 1
- DOFUKSVDRJDFPT-UHFFFAOYSA-N 4-(6-selenophen-3-ylpyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C=1C=C[se]C=1 DOFUKSVDRJDFPT-UHFFFAOYSA-N 0.000 claims 1
- JZWLASCGBSGJJP-UHFFFAOYSA-N 4-(6-thiophen-2-ylpyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=CC=CS1 JZWLASCGBSGJJP-UHFFFAOYSA-N 0.000 claims 1
- GDHIPSSNCMRUGD-UHFFFAOYSA-N 4-(6-thiophen-3-ylpyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C=1C=CSC=1 GDHIPSSNCMRUGD-UHFFFAOYSA-N 0.000 claims 1
- UUMMBUCFQAZHOZ-UHFFFAOYSA-N 4-[6-(1h-indol-2-yl)pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CC2CCN1CCN2C1=CC=C(C=2NC3=CC=CC=C3C=2)N=N1 UUMMBUCFQAZHOZ-UHFFFAOYSA-N 0.000 claims 1
- AAJWPKMRKNHGJB-UHFFFAOYSA-N 4-[6-(1h-indol-3-yl)pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CC2CCN1CCN2C1=CC=C(C=2C3=CC=CC=C3NC=2)N=N1 AAJWPKMRKNHGJB-UHFFFAOYSA-N 0.000 claims 1
- VSQKKGSKQLKGLK-UHFFFAOYSA-N 4-[6-(1h-indol-5-yl)pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CC2CCN1CCN2C1=CC=C(C=2C=C3C=CNC3=CC=2)N=N1 VSQKKGSKQLKGLK-UHFFFAOYSA-N 0.000 claims 1
- GQLYDXLVVUJUNQ-UHFFFAOYSA-N 4-[6-(1h-indol-6-yl)pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CC2CCN1CCN2C1=CC=C(C=2C=C3NC=CC3=CC=2)N=N1 GQLYDXLVVUJUNQ-UHFFFAOYSA-N 0.000 claims 1
- PUSFZEHEZVTHLC-UHFFFAOYSA-N 4-[6-(furan-2-yl)pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=CC=CO1 PUSFZEHEZVTHLC-UHFFFAOYSA-N 0.000 claims 1
- IPMBYUWDOKOAHU-UHFFFAOYSA-N 4-[6-(furan-3-yl)pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C=1C=COC=1 IPMBYUWDOKOAHU-UHFFFAOYSA-N 0.000 claims 1
- YZICOXNXTNFTLQ-UHFFFAOYSA-N 5-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyridazin-3-yl]-1,3-oxazole Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=CN=CO1 YZICOXNXTNFTLQ-UHFFFAOYSA-N 0.000 claims 1
- VCXNGLKVCYWXLQ-UHFFFAOYSA-N 5-[6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)pyridazin-3-yl]-1,3-thiazole Chemical compound C1CN(CC2)CCC1N2C(N=N1)=CC=C1C1=CN=CS1 VCXNGLKVCYWXLQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010004716 Binge eating Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000022372 Reading disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 208000014679 binge eating disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 description 4
- 210000001428 peripheral nervous system Anatomy 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
Description
本発明は、ニコチン性アセチルコリンレセプターに於けるコリン作動性リガンド及びモノアミンレセプター及び輸送体のモジュレーターであると見出されている新規ジアザビシクロビアリール誘導体に関する。その薬理学的プロフィールの故に、本発明の化合物は中枢神経系（ＣＮＳ）、末梢神経系（ＰＮＳ）のコリン作動性系に関連する疾患又は障害、平滑筋収縮に関連する疾患又は障害、内分泌性疾患又は障害、神経変性に関連する疾患又は障害、炎症に関連する疾患又は障害、痛み、化学物質乱用の中止に起因する禁断症状のようなさまざまな疾患又は障害の治療に有効であるといえる。
その薬理学的プロフィールの故に、本発明の化合物は中枢神経系(CNS)、末梢神経系(PNS)のコリン作動性系に関連する疾患又は障害、平滑筋収縮に関連する疾患又は障害、内分泌性疾患又は障害、神経変性に関連する疾患又は障害、炎症に関連する疾患又は障害、痛み、化学物質乱用の中止に起因する禁断症状のようにさまざまな疾患又は障害の治療に有効であるといえる。
その他の好ましい実施態様において、本発明の化合物は急性、慢性又は反復特徴のある軽い、穏やかな又は激しい痛み、偏頭痛に起因する痛み、術後の痛み、又は幻想肢痛の治療に有効である。
Claims (11)
- 式 ＩＩ
｛式中、
′A′′ は、式
で表わされるフェニル基を示すか、又は
′A′′は、
から選ばれたヘテロ環状基を示し、そして
B は、
から選ばれた5-員の芳香族単環状ヘテロ環状基を示すか、又は
Bは、
から選ばれた6-員の芳香族単環状ヘテロ環状基を示すか、又は
Bはインドール-2-イル-, インドール-3-イル-, インドール-5-イル- 又はインドール-6-イル基を示す。｝
で表わされるジアザビシクロビアリール誘導体、又はそのあらゆる対掌体又はその対掌体のあらゆる混合物、又はその薬学的に許容し得る塩。 - 4-(6-チエン-3-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-ピリジン-3-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-セレノフェン-3-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-フラン-2-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-チエン-2-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-フラン-3-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-チアゾール-2-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-セレノフェン-2-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-インドール-2-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-インドール-3-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-インドール-5-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-インドール-6-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-オキサゾール-2-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-オキサゾール-5-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-(6-チアゾール-5-イル-ピリダジン-3-イル)-1,4-ジアザビシクロ[3.2.2]ノナン;
4-[6-(1,3,4)-チアジアゾール-2-イル-ピリダジン-3-イル]-1,4-ジアザビシクロ[3.2.2]ノナン又は
4-[6-(1,3,4)-オキサジアゾール-2-イル-ピリダジン-3-イル]-1,4-ジアザビシクロ[3.2.2]ノナン、又は
その対掌体又はその対掌体の混合物、又はその薬学的に許容し得る塩である、請求項１記載のジアザビシクロビアリール誘導体。 - 請求項１又は２記載のジアザビシクロビアリール誘導体又はその薬学的に許容し得る付加塩の治療上有効な量を、少なくとも１種の薬学的に許容し得るキャリヤー又は希釈剤と共に含有する医薬調合物。
- コリン作動性レセプター及び（又は）モノアミンレセプターのモジュレーションに応答する、ヒトを含めた哺乳類の疾患又は障害又は病態の治療、予防又は緩和用医薬調合物/薬剤の製造に請求項１又は２記載のジアザビシクロビアリール誘導体又はその薬学的に許容し得る付加塩を使用する方法。
- 疾患、障害又は病態が不安、認知障害、学習欠陥、記憶−欠損及び機能障害、アルツハイマー病、注意欠陥、注意欠陥多動性障害、パーキンソン病、ハンチングトン病、筋萎縮性側索硬化症、ジル・ド・ラ・ツレット症候群、うつ病、躁病、躁鬱病、統合失調症、強迫性障害(OCD)、パニック障害、摂食障害、たとえば神経性食欲不振、過食及び肥満、睡眠発作、侵害受容、AIDS-痴呆症、老人性痴呆症、神経障害、自閉症、読書障害、遅発性ジスキネジー、運動亢進症、癲癇、過食症、外傷後症候群、ソーシャルホビア、睡眠障害、仮性痴呆、ガンザー症候群、月経前症候群、遅い黄体期症候群、慢性疲労症候群、無言症、トリコチロマニア及び時差ボケである、請求項４記載の使用する方法。
- 疾患、障害又は病態が痙攣性障害、狭心症、早産、痙攣、下痢、喘息、癲癇、遅発性ジスキネジー、運動亢進症、早熟射精及び勃起障害を含む平滑筋収縮に関連する、請求項４記載の使用する方法。
- 疾患、障害又は病態が内分泌系、たとえば甲状腺中毒症、褐色細胞腫、高血圧及び不整脈に関連する、請求項４記載の使用する方法。
- 疾患、障害又は病態が一時的無酸素症及び誘発された神経変性を含む神経変性疾患である、請求項４記載の使用する方法。
- 疾患、障害又は病態が炎症性皮膚障害、たとえばアクネ及びしゅさ、クーロン病、炎症性腸疾患、潰瘍性毛様体炎及び下痢を含む炎症障害である、請求項４記載の使用する方法。
- 疾患、障害又は病態が急性、慢性又は反復特徴の軽い、穏やかな又は激しい痛み及び偏頭痛に起因する痛み、術後の痛み及び幻想肢痛である、請求項４記載の使用する方法。
- 疾患、障害又は病態がニコチン含有物質、たとえばタバコ、オピオイド、たとえばヘロイン、コカイン又はモルフィン、ベンゾジアゼピン又はベンゾジアゼピン様薬物、又はアルコールを含む依存性物質の使用中止に起因する禁断症状に関連する、請求項４記載の使用する方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201737 | 2002-11-11 | ||
| PCT/DK2003/000769 WO2004043960A1 (en) | 2002-11-11 | 2003-11-10 | 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508109A JP2006508109A (ja) | 2006-03-09 |
| JP2006508109A5 true JP2006508109A5 (ja) | 2010-10-14 |
Family
ID=32309262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004550659A Ceased JP2006508109A (ja) | 2002-11-11 | 2003-11-10 | １，４−ジアザビシクロ（３，２，２）ノナン誘導体、その製造方法及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1562945B1 (ja) |
| JP (1) | JP2006508109A (ja) |
| AT (1) | ATE345342T1 (ja) |
| AU (1) | AU2003280309A1 (ja) |
| DE (1) | DE60309740T2 (ja) |
| DK (1) | DK1562945T3 (ja) |
| WO (1) | WO2004043960A1 (ja) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| EP1603585A2 (en) | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| SE0303076D0 (sv) * | 2003-11-19 | 2003-11-19 | Astrazeneca Ab | 5-substituted imidazoles |
| SE0303075D0 (sv) * | 2003-11-19 | 2003-11-19 | Astrazeneca Ab | 4-substituted imidazoles |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| US7612074B2 (en) | 2004-11-30 | 2009-11-03 | Neurosearch A/S | Diazabicyclic aryl derivatives as cholinergy ligands |
| US7662812B2 (en) | 2005-02-16 | 2010-02-16 | Neurosearch A/S | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors |
| ATE481407T1 (de) | 2005-02-16 | 2010-10-15 | Neurosearch As | Neue diazabicyclische arylderivate und medizinische verwendung dafür |
| NZ567048A (en) | 2005-12-06 | 2010-12-24 | Neurosearch As | Novel diazabicyclic aryl derivatives and their medical use |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| US7855208B2 (en) | 2006-02-14 | 2010-12-21 | Neurosearch A/S | 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists |
| MX2008014887A (es) * | 2006-05-30 | 2008-12-05 | Neurosearch As | Nuevos derivados de 1,4-diaza-biciclo[3.2.2]nonil oxadiazolilo y su uso medico. |
| US20090197872A1 (en) | 2006-05-30 | 2009-08-06 | Dan Peters | Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use |
| US8778987B2 (en) | 2007-03-13 | 2014-07-15 | Symrise Ag | Use of 4-hydroxychalcone derivatives for masking an unpleasant taste |
| EP1977655B1 (de) | 2007-03-29 | 2011-05-18 | Symrise AG | Aromakompositionen von Alkamiden mit Hesperetin und/oder 4-Hydroxydihydrochalkonen und deren Salzen zur Verstärkung süßer sensorischer Eindrücke |
| MX2010005040A (es) | 2007-11-14 | 2010-05-21 | Neurosearch As | Nuevos derivados de 1,4-diaza-biciclo[3.2.2]nonil-pirimidina y su uso medico. |
| US20110257161A1 (en) * | 2008-12-04 | 2011-10-20 | Neurosearch A/S | Novel diaza-bicyclononyl-phenyl derivatives and their medical use |
| CA2989633A1 (en) | 2010-05-17 | 2011-11-24 | Forum Pharmaceuticals Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| EP2559346B1 (en) | 2011-08-15 | 2014-03-26 | Symrise AG | Oleanene-type triterpene glycosides as masking agents |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| US8729263B2 (en) * | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| ES2917979T3 (es) | 2013-07-31 | 2022-07-12 | Novartis Ag | Derivados de Piridazina 1,4-disustituidos y su uso para tratar afecciones relacionadas con la deficiencia de SMN |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2786770B1 (fr) * | 1998-12-04 | 2001-01-19 | Synthelabo | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique |
| FR2809730B1 (fr) * | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique |
| FR2809731B1 (fr) * | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique |
| FR2809732B1 (fr) * | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE |
| US20020086871A1 (en) * | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
| FR2832714B1 (fr) * | 2001-11-23 | 2004-07-16 | Sanofi Synthelabo | Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| FR2832713B1 (fr) * | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| FR2832712B1 (fr) * | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique |
| DE10162442A1 (de) * | 2001-12-19 | 2003-07-03 | Bayer Ag | Monocyclische N-Aryl-amide |
-
2003
- 2003-11-10 DK DK03770918T patent/DK1562945T3/da active
- 2003-11-10 AT AT03770918T patent/ATE345342T1/de active
- 2003-11-10 JP JP2004550659A patent/JP2006508109A/ja not_active Ceased
- 2003-11-10 DE DE60309740T patent/DE60309740T2/de not_active Expired - Lifetime
- 2003-11-10 EP EP03770918A patent/EP1562945B1/en not_active Expired - Lifetime
- 2003-11-10 WO PCT/DK2003/000769 patent/WO2004043960A1/en active IP Right Grant
- 2003-11-10 AU AU2003280309A patent/AU2003280309A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508109A5 (ja) | ||
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| JP2005524713A5 (ja) | ||
| CN100432075C (zh) | 作为烟碱样乙酰胆碱受体配体的二氮杂双环芳基衍生物 | |
| JP2009538867A5 (ja) | ||
| CN100513406C (zh) | 新的奎宁环衍生物及其用途 | |
| EP1805183B1 (en) | Novel diazabicyclic aryl derivatives and their medical use | |
| JP2007520525A5 (ja) | ||
| JP2007530635A5 (ja) | ||
| JP2004538268A5 (ja) | ||
| CA2389553A1 (en) | Heteroaryl-diazabicycloalkanes | |
| CA2496585A1 (en) | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | |
| RU2006131454A (ru) | Новые производные мочевины и их медицинское применение | |
| JP2008530171A5 (ja) | ||
| JP2006508109A (ja) | １，４−ジアザビシクロ（３，２，２）ノナン誘導体、その製造方法及びその使用 | |
| JP2008530172A5 (ja) | ||
| CN101027300A (zh) | 新的氮杂双环芳基衍生物及其医药用途 | |
| EP1599476B1 (en) | Novel diazabicyclic aryl derivatives | |
| JP2005537297A (ja) | アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物 | |
| JP2009537599A5 (ja) | ||
| JP2005530814A5 (ja) | ||
| CN1326857C (zh) | 新的1,4－二氮杂双环烷烃衍生物、其制备和应用 | |
| JP2006503062A5 (ja) | ||
| RU2010114662A (ru) | Новые производные 1,4-диазабицикло(3.2.2)нонилпиримидина и их медицинское применение | |
| RU2010135037A (ru) | Новые производные, 1,4-диазабицикло[3.2.2]нонилоксадиазолил, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов |